. Author manuscript; available in PMC: 2024 Sep 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2023 May 8;21(10):2462–2472. doi: 10.1016/j.cgh.2023.04.030

Table 1.

Costs associated with different therapeutic strategies in patients with diarrhea- and constipation-predominant irritable bowel syndrome.

Therapeutic strategies (price in US dollars/year)	Insurer perspective ($)	Patient perspective ($)	Ref. #
Diarrhea-predominant irritable bowel syndrome
No treatment	2141.05	4789.13	¹³
CBT	1808.95	2734.14
Low FODMAP	1242.62	2730.29
Alosetron	15708.92	1868.03
Rifaximin	6144.53	2725.92
Eluxadoline	11567.00	1896.02
TCA	964.07	2049.97
Constipation-predominant irritable bowel syndrome
No treatment	3929.37	5805.00	¹⁴
CBT	2129.06	3275.79
Low FODMAP	2124.09	3230.31
Lubiprostone	7218.00	4596.04
Plecanatide	7139.64	3611.01
Linaclotide	6460.63	2822.20
SSRI	2046.58	3010.30

CBT: cognitive behavioral therapy; FODMAP: Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols; TCA: tricyclic antidepressant; SSRI: selective serotonin reuptake inhibitor